EUVIMEDEUVIMED entdecken
Editorial

Red light therapy for myopia: Merits, risks and questions

Frank Schaeffel iD, Christine F Wildsoet iD

Ophthalmic and Physiological Optics · 2024-07 · 44 (5) · 801-807

DOI: 10.1111/opo.13306 ↗

Kurz gefasst

Editorial in der Zeitschrift Ophthalmic and Physiological Optics, online erschienen am 02.04.2024. Verfasst von Frank Schaeffel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland. Hauptthemen laut MEDLINE: Myopia, Phototherapy. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyopiaPhototherapyHumansRefraction, Ocular

Autor:innen und Institutionen

  • Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.
  • Section of Neurobiology of the Eye, Ophthalmic Research Institute, University of Tuebingen, Tuebingen, Germany.
  • Herbert Wertheim School of Optometry and Vision Science, University California Berkeley, Berkeley, California, USA.
  • School of Optometry and Vision Science, Queensland University of Technology, Brisbane, Queensland, Australia.

ORCID-Profile: Frank Schaeffel, Christine F Wildsoet

Zitieren

APA

Schaeffel, F., & Wildsoet, C. F. (2024). Red light therapy for myopia: Merits, risks and questions. Ophthalmic and Physiological Optics, 44(5), 801-807. https://doi.org/10.1111/opo.13306

Vancouver

Schaeffel F, Wildsoet CF. Red light therapy for myopia: Merits, risks and questions. Ophthalmic and Physiological Optics. 2024;44(5):801-807. doi:10.1111/opo.13306

BibTeX
@article{Schaeffel2024,
  author = {Schaeffel, Frank and Wildsoet, Christine F},
  title = {Red light therapy for myopia: Merits, risks and questions},
  journal = {Ophthalmic and Physiological Optics},
  year = {2024},
  volume = {44},
  number = {5},
  pages = {801--807},
  doi = {10.1111/opo.13306}
}
Kostenlos starten →